Guardant Health, Inc.
HealthcareNASDAQ:GH · NASDAQ Global Select
+$0.72 today
Vol 1.45M · Avg 2.19M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
419.2%
avg -85.3%
ROIC
-25.4%
avg -25.7%
ROA
-20.7%
avg -23.3%
Analysis
ROE is currently the strongest return metric at 419.2% versus its period average of -85.3%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael Bell | Chief Financial Officer | $976,029.00 | — | 57 | $47,509.00 | 0.04% |
John G. Saia | Chief Legal Officer & Corporate Secretary | $914,430.00 | — | 53 | $35,956.00 | 0.03% |
Darya Chudova | Chief Technology Officer | $908,421.00 | — | 52 | $74,402.00 | 0.06% |
Craig Eagle | Chief Medical Officer | $844,862.00 | — | 59 | $77,780.00 | 0.06% |
Terilyn Juarez Monroe | Chief People Officer | $787,541.00 | — | 59 | $20,990.00 | 0.02% |
AmirAli Talasaz | Co-CEO & Director | $13,518.00 | — | 46 | $2.10M | 1.58% |
Helmy Eltoukhy | Co-Founder, Co-CEO & Chairman | $13,423.00 | — | 47 | $2.06M | 1.56% |
Andy Ament | Senior Vice President of Operations | — | — | — | — | — |
Zarak Khurshid | Vice President of Investor Relations | — | — | — | — | — |
Gulshan Shaver | Senior Vice President of Legal Affairs & Chief Compliance Officer | — | — | — | — | — |
Kumud Kalia | Chief Information Officer | — | — | 60 | $44,508.00 | 0.03% |
Stephen Murphy | Senior Vice President of Screening Marketing | — | — | — | — | — |
Jennifer Higgins | Senior Vice President of Public Affairs | — | — | — | — | — |
Noam Krantz | Senior Vice President of Corporate Development | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
43
$52.17M
Net Sentiment
$52.17M
Net selling
Most Active
Talasaz AmirAli
13 transactions
1–10 of 43
Analysis
Insiders reported 0 buys worth $0.00 and 43 sells worth $52.17M over the last 12 months. That adds up to net selling of $52.17M. Talasaz AmirAli was the most active insider with 13 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | +79.2% | +27.1% (10yr)15 analysts |
| Net Income | N/A | N/A | N/A | N/A15 analysts |
| EBIT | N/A | N/A | N/A | N/A15 analysts |
Analysis
Recent growth has been strongest in Revenue at +79.2% over three years. Forward estimates point to Revenue at +27.1% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Exact Sciences Corporation
EXAS
$20.03B
Viatris Inc.
NASDAQ:VTRS
$19.19B
Solventum Corporation
NYSE:SOLV
$13.66B
Ascendis Pharma A/S
NASDAQ:ASND
$13.47B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.08B
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$12.11B
ICON Public Limited Company
NASDAQ:ICLR
$11.19B
Revvity, Inc.
NYSE:RVTY
$11.12B
Encompass Health Corporation
NYSE:EHC
$10.07B
Qiagen N.V.
NYSE:QGEN
$7.64B
Who manages GH?
Guardant Health, Inc. (GH) lists 14 active executives. The top listed executive is Andy Ament, Senior Vice President of Operations.
Are GH insiders buying or selling?
Recent insider activity shows net selling of $65.65M.
Explore More
Continue the stock analysis
Jump to another research area for this company.